

# PRODUCT INFORMATION




## Eliglustat (hemitartrate)

Item No. 21487

**CAS Registry No.:** 928659-70-5  
**Formal Name:** N-[(1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-octanamide, 2R,3R-dihydroxybutanedioate (2:1)

**Synonym:** Genz-112638  
**MF:**  $C_{23}H_{36}N_2O_4 \cdot 1/2C_4H_6O_6$   
**FW:** 479.6  
**Purity:**  $\geq 98\%$   
**UV/Vis.:**  $\lambda_{max}$ : 286 nm  
**Supplied as:** A crystalline solid  
**Storage:**  $-20^\circ C$   
**Stability:**  $\geq 4$  years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Eliglustat (hemitartrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the eliglustat (hemitartrate) in the solvent of choice, which should be purged with an inert gas. Eliglustat (hemitartrate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of eliglustat (hemitartrate) in these solvents is approximately 20 mg/ml.

Eliglustat (hemitartrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, eliglustat (hemitartrate) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Eliglustat (hemitartrate) has a solubility of approximately 0.03 mg/ml in a 1:30 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Eliglustat is an inhibitor of glucosylceramide synthase ( $IC_{50} = 40$  nM for inhibition of glucosylceramide production in K562 cells).<sup>1</sup> It is selective for glucosylceramide synthase over  $\alpha$ -glucosidase I and II,  $\alpha$ -1,6-glucosidase, lysosomal glucocerebrosidase, non-lysosomal glucosylceramidase, sucrase, and maltase ( $IC_{50}$ s =  $>10$   $\mu$ M for all). It decreases cell surface levels of the gangliosides  $GM_1$  and  $GM_3$  in K562 and B16/F10 cells with  $IC_{50}$  values of 24 and 29 nM, respectively. Eliglustat (150 mg/kg per day) decreases glucosylceramide levels in the liver and lungs of D409V/null mice, a model of Gaucher disease. Formulations containing eliglustat have been used in the treatment of type 1 Gaucher disease.

### Reference

1. McEachern, K.A., Fung, J., Komarnitsky, S., *et al.* A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. *Mol. Genet. Metab.* **91(3)**, 259-267 (2007).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM